3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial.
Michael C Mithoefer, Ann T Mithoefer, Allison A Feduccia, Lisa Jerome, Mark Wagner, Joy Wymer, Julie Holland, Scott Hamilton, Berra Yazar-Klosinski, Amy Emerson, Rick Doblin
Lancet Psychiatry May 1, 2018 DOI: 10.1016/s2215-0366(18)30135-4 via PubMed
Summary
AI-generated from the abstractA randomized, double-blind, phase 2 clinical trial tested MDMA-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers. Participants were randomly assigned to receive different doses of MDMA during psychotherapy sessions. The findings revealed that the active dose of MDMA led to significant and lasting reductions in PTSD symptoms compared to the lower dose, indicating that this innovative therapeutic approach can effectively treat this condition and provide significant relief for individuals with profound trauma.
Study at a glance
| Characteristics | Randomized, double-blind, dose-response, phase 2 clinical trial Peer reviewed |
|---|---|
| Population | Military veterans, firefighters, and police officers with post-traumatic stress disorder |
| Keywords | This condition PTSD Symptoms Profound trauma Significant relief Promising treatment option |
| Citations | 443 |
| Key finding | The active dose of MDMA-assisted psychotherapy led to significant and lasting reductions in PTSD symptoms compared to a lower dose. |
Abstract
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial.